We are doing science for policy
The Joint Research Centre (JRC) is the European Commission's science and knowledge service which employs scientists to carry out research in order to provide independent scientific advice and support to EU policy.
A new JRC study describes almost 300 non-animal models used for research on respiratory diseases and the development of new drugs and therapies.
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and lung cancer are the most common of all diseases and causes of death worldwide.
The database now includes 211 new chemicals with negative results in the Ames test, a widely employed in vitro method based on bacteria to identify if a chemical can cause mutations in DNA.
Damage to DNA caused by chemicals is concerning since it can contribute to the initiation and development of many serious health effects including birth defects and cancer.
The JRC has published initial results of a survey it conducted to gather the views of EU-funded researchers on how their work has contributed to scientific innovation and benefitted society
The JRC has compiled the results of three recent surveys aimed at gaining the views and experiences of citizens, stakeholders and companies related to endocrine disruptors.
The surveys probed concerns about the potential health and environmental effects of endocrine disrupting chemicals, solicited views on the ways in which these chemicals are assessed and regulated within the EU, and explored the social and economic consequences of regulatory action.
The JRC’s EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) has just published its Status Report 2019 on the development, validation and regulatory acceptance of alternative methods used for scientific purposes.
The JRC has launched an online survey to gather feedback from researchers who received financial support from projects funded under FP5, FP6, FP7, or H2020 framework programmes.
It is part of a bigger initiative to gain a better understanding of the outputs and impacts of biomedical research.
It targets researchers who have participated in EU funded projects during the past 20 years in the fields of breast cancer, prostate cancer or Alzheimer’s disease and other dementias.
Effective from January 2020, JRC scientist Anna Price has been appointed Editor-in-Chief of the Elsevier journal Reproductive Toxicology.
The prestigious appointment is recognition of Anna’s work at the JRC and its EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) and the significant contributions made in fields including developmental toxicology, both in terms of basic research and improving chemical hazard assessment using alternative (non-animal) methods.